bioAffinity Technologies Plans $4 Million Cost Cut to Boost CyPath® Lung Sales
bioAffinity Technologies Plans $4 Million Cost Cut to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive testing for early-stage lung cancer and other lung diseases, has outlined its latest strategic actions aimed…
Datavant Launches Upgraded Clinical Insights Platform for Payers and Providers
Datavant Launches Upgraded Clinical Insights Platform for Payers and Providers Datavant, a leader in health data platform solutions, has announced the launch of its enhanced Datavant Clinical Insights Platform, designed to transform how health plans and risk-bearing providers identify, access,…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy: Access, Regulations, and Trials
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy: Access, Regulations, and Trials Italfarmaco S.p.A. has announced significant progress in the regulatory and clinical development of givinostat, its investigational drug for the treatment of Duchenne muscular dystrophy (DMD). The company provided…
Openwater Appoints New CEO as Demand for Portable Imaging and Therapy Devices Grows
Openwater Appoints New CEO as Demand for Portable Imaging and Therapy Devices Grows Openwater, the open-source medtech company known for providing portable diagnostic and therapeutic devices at a fraction of traditional costs, has announced the appointment of Aaron Timm as…
AcuityMD Unveils New Outpatient Spinal Surgery Data at AAOS Annual Meeting
AcuityMD Unveils New Outpatient Spinal Surgery Data at AAOS Annual Meeting AcuityMD, a leading intelligence platform for MedTech, is showcasing new data on the rise of outpatient spinal surgeries at the 2025 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting.…
QIAGEN Gets U.S. Approval for Second QIAstat-Dx Mini GI Panel
QIAGEN Gets U.S. Approval for Second QIAstat-Dx Mini GI Panel QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, enhancing…
InterSystems Launches IntelliCare: AI-Powered Next-Gen EHR
InterSystems Launches IntelliCare: AI-Powered Next-Gen EHR InterSystems, a leading provider of innovative data technology managing over a billion health records globally, today unveiled InterSystems IntelliCare, a next-generation, AI-powered electronic health record (EHR) and healthcare information system. IntelliCare is designed to…
Philips Chooses AWS as Preferred Cloud Provider to Drive Innovation and Enhance Patient Outcomes
Philips Chooses AWS as Preferred Cloud Provider to Drive Innovation and Enhance Patient Outcomes Amazon Web Services, Inc. (AWS), part of Amazon.com, Inc. (NASDAQ: AMZN), has announced that Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology,…
ENCell’s EN001 Gets FDA Orphan Drug Status for Charcot-Marie-Tooth Disease
ENCell’s EN001 Gets FDA Orphan Drug Status for Charcot-Marie-Tooth Disease ENCell, a leading biopharmaceutical company specializing in cell and gene therapy, contract research, and manufacturing, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
MedLumics® Publishes FIM Results for AblaView® Ablation System in AF Patients
MedLumics® Publishes FIM Results for AblaView® Ablation System in AF Patients “We would like to extend our heartfelt thanks to the investigation site team, especially the investigators and proctors, for their invaluable contributions to this groundbreaking first-in-human trial. Their efforts…
CU Cancer Center and Flatiron Health Collaborate to Improve Clinical Trials
CU Cancer Center and Flatiron Health Collaborate to Improve Clinical Trials Flatiron Health, a leading healthtech company revolutionizing clinical research, has announced a new collaboration with the University of Colorado Cancer Center (CU Cancer Center) and their clinical care partner,…
Elegen Reduces Pricing for ENFINIA™ DNA to Expand Access to Next-Generation Cell-Free DNA Manufacturing
Elegen Reduces Pricing for ENFINIA™ DNA to Expand Access to Next-Generation Cell-Free DNA Manufacturing Elegen, a pioneer in next-generation cell-free DNA manufacturing, has announced a 25% price reduction for its ENFINIA™ DNA products. This move aims to make the industry-leading,…